期刊文献+

临床药师参与1例重症医院获得性肺炎的药学实践 被引量:1

Pharmaceutical Practice of Clinical Pharmacist in Treatment of One Case of Severe Nosocomial Pneumonia
暂未订购
导出
摘要 目的:评估1例重症医院获得性肺炎患者的抗感染药学实践,以达到最佳药物治疗效果。方法:临床药师与医师密切合作,根据医院获得性肺炎诊疗相关指南及病原学结果及时调整用药方案,并进行药学监护,密切观察疗效。结果:经过反复调整用药方案,获得了有效的治疗效果,并减轻了不良反应。结论:临床药师应深入临床,积极配合医师,从药学专业角度评价治疗效果,关注不良反应,从而使医院获得性肺炎患者得到最合理的治疗。 OBJECTIVE:To evaluate clinical pharmacists' participation in the treatment of one case of severe hospital acquired pneumonia(HAP) so as to achieve optimal therapeutic efficacy.METHODS: Clinical pharmacists cooperated well with clinicians to timely optimize the therapeutic regimen for HAP patient based on the guidelines for the management of nosocomial pneumonia and pathogen results,provide pharmaceutical care and pay close attention to curative efficacy.RESULTS: By repeated adjusting the therapeutic regimen,optimal therapeutic efficacy yet mild adverse drug reactions were achieved.CONCLUSION: Clinical pharmacists should take part in clinical practice,cooperate with clinicians,evaluate curative efficacy from aspect of pharmacy,pay attention to adverse drug reactions to achieve most rational treatment for HAP patients.
出处 《中国医院用药评价与分析》 2012年第12期1135-1139,共5页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 医院获得性肺炎 临床药师 药学监护 不良反应 耐药 Nosocomial pneumonia Clinical pharmacist Pharmaceutical care Adverse drug reaction Drug resistance
  • 相关文献

参考文献9

二级参考文献17

  • 1金少鸿.关于参加为WHO起草“对人类健康极为重要抗生素目录”专家小组会议的汇报[J].中国药事,2005,19(3):182-184. 被引量:9
  • 2冯加喜,林云,吕冬青.耐亚胺培南鲍氏不动杆菌医院获得性肺部感染危险因素及耐药性分析[J].中华医院感染学杂志,2006,16(12):1416-1418. 被引量:26
  • 3李敏,张健.替考拉宁在革兰阳性菌所致肺炎中的研究进展[J].医学研究杂志,2007,36(5):117-118. 被引量:8
  • 4Falagas M E, Bliziotis I A, Kasiakou S K, et al. Outcome of infections due to pandrug-resistant(PDR) Gram-negative bacteria[J]. BMC inject Dis, 2005, 5( 1): 24-25.
  • 5Corbella X, Ariza J, Ardanuy C, et al. Efficacy of sulbactam along and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii[J]. J Antimicrob Chemother, 1998, 42:793-796.
  • 6Joly-Guillou M L, Decre D, Herrma J L, et al. Bactericidal in-vitro activity of β-lactams and β-lactamses inhibitors, alone or associated, against clinical strains of A.baumannii effect of combination with aminoglycosides[J]. J Antimicrob Chemother, 1995, 36:619-623.
  • 7Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teieoplanin; systematic review and meta-analysis[J]. Antimicrob Agents Chemother,2009, 53(10) :4069-4079.
  • 8Wisplinghoff H, Bischoff T, Tallent SM,et al. Nosocomial blood- stream infections in US hospitals : analysis of 24,179 cases from a prospective nationwide surveillance study[J]. Clin Infect Dis, 2004,39(3) :309-317.
  • 9Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia[J]. Chest, 2005,128(6) :3854-3862.
  • 10American Thoracic Society;Infectious Diseases Society of America.Guidelines for the management of adults with hospital-acquired,ventilator-associated,and healthcare-associated pneumonia.Am J Respir Crit Care Med,2005,171:388-416.

共引文献427

同被引文献14

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部